AZD4547: An Orally Bioavailable, Potent, and Selective Inhibitor of the Fibroblast Growth Factor Receptor Tyrosine Kinase Family

被引:440
作者
Gavine, Paul R. [1 ]
Mooney, Lorraine [1 ]
Kilgour, Elaine [1 ]
Thomas, Andrew P. [1 ]
Al-Kadhimi, Katherine [1 ]
Beck, Sarah [1 ]
Rooney, Claire [1 ]
Coleman, Tanya [1 ]
Baker, Dawn [1 ]
Mellor, Martine J. [1 ]
Brooks, A. Nigel [1 ]
Klinowska, Teresa [1 ]
机构
[1] AstraZeneca R&D, Shanghai, Peoples R China
关键词
CANCER CELL-LINES; MULTIPLE-MYELOMA; IN-VIVO; MUTATIONS; APOPTOSIS; EXPRESSION; RESISTANCE; CARCINOMA; AZD2171; TRANSLOCATION;
D O I
10.1158/0008-5472.CAN-11-3034
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The fibroblast growth factor (FGF) signaling axis is increasingly implicated in tumorigenesis and chemoresistance. Several small-molecule FGF receptor (FGFR) kinase inhibitors are currently in clinical development; however, the predominant activity of the most advanced of these agents is against the kinase insert domain receptor (KDR), which compromises the FGFR selectivity. Here, we report the pharmacologic profile of AZD4547, a novel and selective inhibitor of the FGFR1, 2, and 3 tyrosine kinases. AZD4547 inhibited recombinant FGFR kinase activity in vitro and suppressed FGFR signaling and growth in tumor cell lines with deregulated FGFR expression. In a representative FGFR-driven human tumor xenograft model, oral administration of AZD4547 was well tolerated and resulted in potent dose-dependent antitumor activity, consistent with plasma exposure and pharmacodynamic modulation of tumor FGFR. Importantly, at efficacious doses, no evidence of anti-KDR-related effects were observed, confirming the in vivo FGFR selectivity of AZD4547. Taken together, our findings show that AZD4547 is a novel selective small-molecule inhibitor of FGFR with potent antitumor activity against FGFR-deregulated tumors in preclinical models. AZD4547 is under clinical investigation for the treatment of FGFR-dependent tumors. Cancer Res; 72(8); 2045-56. (C) 2012 AACR.
引用
收藏
页码:2045 / 2056
页数:12
相关论文
共 44 条
[1]   Blocking oncogenic Ras signaling for cancer therapy [J].
Adjei, AA .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2001, 93 (14) :1062-1074
[2]   AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients [J].
Batchelor, Tracy T. ;
Sorensen, A. Gregory ;
di Tomaso, Emmanuelle ;
Zhang, Wei-Ting ;
Duda, Dan G. ;
Cohen, Kenneth S. ;
Kozak, Kevin R. ;
Cahill, Daniel P. ;
Chen, Poe-Jou ;
Zhu, Mingwang ;
Ancukiewicz, Marek ;
Mrugala, Maciej M. ;
Plotkin, Scott ;
Drappatz, Jan ;
Louis, David N. ;
Ivy, Percy ;
Scadden, David T. ;
Benner, Thomas ;
Loeffler, Jay S. ;
Wen, Patrick Y. ;
Jain, Rakesh K. .
CANCER CELL, 2007, 11 (01) :83-95
[3]   Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors [J].
Billerey, C ;
Chopin, D ;
Aubriot-Lorton, MH ;
Ricol, D ;
de Medina, SGD ;
Van Rhijn, B ;
Bralet, MP ;
Lefrere-Belda, MA ;
Lahaye, JB ;
Abbou, CC ;
Bonaventure, J ;
Zafrani, ES ;
van der Kwast, T ;
Thiery, JP ;
Radvanyi, F .
AMERICAN JOURNAL OF PATHOLOGY, 2001, 158 (06) :1955-1959
[4]   Inhibition of activated fibroblast growth factor receptor 2 in endometrial cancer cells induces cell death despite PTEN abrogation [J].
Byron, Sara A. ;
Gartside, Michael G. ;
Wellens, Candice L. ;
Mallon, Mary A. ;
Keenan, Jack B. ;
Powell, Matthew A. ;
Goodfellow, Paul J. ;
Pollock, Pamela M. .
CANCER RESEARCH, 2008, 68 (17) :6902-6907
[5]   Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3 [J].
Chesi, M ;
Nardini, E ;
Brents, LA ;
Schrock, E ;
Ried, T ;
Kuehl, WM ;
Bergsagel, PL .
NATURE GENETICS, 1997, 16 (03) :260-264
[6]   Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma [J].
Chesi, M ;
Brents, LA ;
Fly, SA ;
Bais, C ;
Robbiani, DF ;
Mesri, E ;
Kuehl, WM ;
Bergsagel, PL .
BLOOD, 2001, 97 (03) :729-736
[7]   Inhibition of vascular endothelial growth factor-A signaling induces hypertension: Examining the effect of cediranib (Recentin; AZD2171) treatment on blood pressure in rat and the use of concomitant anti hypertensive therapy [J].
Curwen, Jon O. ;
Musgrove, Helen L. ;
Kendrew, Jane ;
Richmond, Graham H. P. ;
Ogilvie, Donald J. ;
Wedge, Stephen R. .
CLINICAL CANCER RESEARCH, 2008, 14 (10) :3124-3131
[8]   AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases:: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models [J].
Davies, Barry R. ;
Logie, Armelle ;
McKay, Jennifer S. ;
Martin, Paul ;
Steele, Samantha ;
Jenkins, Richard ;
Cockerill, Mark ;
Cartlidge, Sue ;
Smith, Paul D. .
MOLECULAR CANCER THERAPEUTICS, 2007, 6 (08) :2209-2219
[9]   The t(8;22) in chronic myeloid leukemia fuses BCR to FGFR1: transforming activity and specific inhibition of FGFR1 fusion proteins [J].
Demiroglu, A ;
Steer, EJ ;
Heath, C ;
Taylor, K ;
Bentley, M ;
Allen, SL ;
Koduru, P ;
Brody, JP ;
Hawson, G ;
Rodwell, R ;
Doody, ML ;
Carnicero, F ;
Reiter, A ;
Goldman, JM ;
Melo, JV ;
Cross, NCP .
BLOOD, 2001, 98 (13) :3778-3783
[10]  
Fabbro D, 2001, Curr Opin Investig Drugs, V2, P1142